1
|
Passiglia F, Righi L, Listì A, Tabbò F, Bironzo P, Reale M, Sini C, Vallone S, Arizio F, Parravicini MP, Mazilu L, Linardou H, Roca E, Buffoni L, Mohorcic K, Barbieri V, Pignataro D, Araujo A, Ares LP, Felip E, Secen N, Comanescu A, Szmytke E, Scagliotti G, Novello S. EP16.03-011 The European Program for ROutine Testing of Patients with Advanced Lung Cancer (EPROPA) 1 Year Activity. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.1072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
2
|
Santo A, Lombardo F, Roca E, Cucinella A, Comel A, Benato C, Stefanizzi L, Divis P, Sposito M, Vaccari S, Fedrigo E, Tosoni E, Milella M. EP14.01-005 Weekly Sequential ACOCEV Chemotherapy (ADR, CTX, CBDCA, VP16, VCR) for Elderly - Poor PS SCLC Patients: An Observational Study. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.941] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
3
|
Pizzutilo E, Agostara A, Oresti S, Signorelli D, Giannetta L, Stabile S, Lauricella C, Amatu A, Brambilla M, Lo Russo G, Proto C, Mazzeo L, Beninato T, Siringo M, Giusti R, Filetti M, Genova C, Barletta G, Russano M, Di Fazio G, Tosoni E, Metro G, Pilotto S, Carta A, Mazzoni F, Roca E, Gelibter A, Gori S, Berardi R, Cerea G, Sartore-Bianchi A, Siena S. EP08.02-046 Activity of OsimeRTInib in NSCLC with Uncommon EGFR Mutations: Retrospective Observational Multicenter Study (ARTICUNO). J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.728] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
4
|
Pizzutilo E, Cerea G, Oresti S, Agostara A, Signorelli D, Stabile S, Lauricella C, Brambilla M, Mazzeo L, Giusti R, Montrone M, Russano M, Bennati C, Russo A, Viscardi G, Roca E, Gelibter A, Cortinovis D, Sartore Bianchi A, Siena S. 996P Activity of OsimeRTInib in NSCLC with UNcommon EGFR Mutations: Retrospective observational multicenter study (ARTICUNO). Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1122] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
5
|
Cantini L, Mentrasti G, Lo Russo G, Signorelli D, Pasello G, Rijavec E, Russano M, Antonuzzo L, Rocco D, Giusti R, Adamo V, Genova C, Tuzi A, Morabito A, Gori S, La Verde N, Chiari R, Cortellini A, Cognigni V, Pecci F, Indini A, De Toma A, Zattarin E, Oresti S, Pizzutilo E, Frega S, Erbetta E, Galletti A, Citarella F, Fancelli S, Caliman E, Della Gravara L, Malapelle U, Filetti M, Piras M, Toscano G, Zullo L, De Tursi M, Di Marino P, D’Emilio V, Cona M, Guida A, Caglio A, Salerno F, Spinelli G, Bennati C, Morgillo F, Russo A, Dellepiane C, Vallini I, Sforza V, Inno A, Rastelli F, Tassi V, Nicolardi L, Pensieri M, Emili R, Roca E, Migliore A, Galassi T, Rocchi M, Berardi R. Erratum to ‘Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario’. ESMO Open 2022; 7:100471. [PMID: 35378403 PMCID: PMC8973259 DOI: 10.1016/j.esmoop.2022.100471] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
|
6
|
Cantini L, Mentrasti G, Russo GL, Signorelli D, Pasello G, Rijavec E, Russano M, Antonuzzo L, Rocco D, Giusti R, Adamo V, Genova C, Tuzi A, Morabito A, Gori S, Verde NL, Chiari R, Cortellini A, Cognigni V, Pecci F, Indini A, De Toma A, Zattarin E, Oresti S, Pizzutilo EG, Frega S, Erbetta E, Galletti A, Citarella F, Fancelli S, Caliman E, Della Gravara L, Malapelle U, Filetti M, Piras M, Toscano G, Zullo L, De Tursi M, Di Marino P, D'Emilio V, Cona MS, Guida A, Caglio A, Salerno F, Spinelli G, Bennati C, Morgillo F, Russo A, Dellepiane C, Vallini I, Sforza V, Inno A, Rastelli F, Tassi V, Nicolardi L, Pensieri V, Emili R, Roca E, Migliore A, Galassi T, Rocchi MLB, Berardi R. Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario. ESMO Open 2022; 7:100406. [PMID: 35219245 PMCID: PMC8810307 DOI: 10.1016/j.esmoop.2022.100406] [Citation(s) in RCA: 26] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2021] [Revised: 01/19/2022] [Accepted: 01/23/2022] [Indexed: 12/18/2022] Open
Abstract
Introduction COVID-19 has disrupted the global health care system since March 2020. Lung cancer (LC) patients (pts) represent a vulnerable population highly affected by the pandemic. This multicenter Italian study aimed to evaluate whether the COVID-19 outbreak had an impact on access to cancer diagnosis and treatment of LC pts compared with pre-pandemic time. Methods Consecutive newly diagnosed LC pts referred to 25 Italian Oncology Departments between March and December 2020 were included. Access rate and temporal intervals between date of symptoms onset and diagnostic and therapeutic services were compared with the same period in 2019. Differences between the 2 years were analyzed using the chi-square test for categorical variables and the Mann–Whitney U test for continuous variables. Results A slight reduction (−6.9%) in newly diagnosed LC cases was observed in 2020 compared with 2019 (1523 versus 1637, P = 0.09). Newly diagnosed LC pts in 2020 were more likely to be diagnosed with stage IV disease (P < 0.01) and to be current smokers (someone who has smoked more than 100 cigarettes, including hand-rolled cigarettes, cigars, cigarillos, in their lifetime and has smoked in the last 28 days) (P < 0.01). The drop in terms of new diagnoses was greater in the lockdown period (percentage drop −12% versus −3.2%) compared with the other months included. More LC pts were referred to a low/medium volume hospital in 2020 compared with 2019 (P = 0.01). No differences emerged in terms of interval between symptoms onset and radiological diagnosis (P = 0.94), symptoms onset and cytohistological diagnosis (P = 0.92), symptoms onset and treatment start (P = 0.40), and treatment start and first radiological revaluation (P = 0.36). Conclusions Our study pointed out a reduction of new diagnoses with a shift towards higher stage at diagnosis for LC pts in 2020. Despite this, the measures adopted by Italian Oncology Departments ensured the maintenance of the diagnostic-therapeutic pathways of LC pts. The COVID-19 outbreak had an impact on access to lung cancer (LC) diagnosis and treatment. A slight reduction (−6.9%) in newly diagnosed LC cases was observed in 2020 compared with 2019. Newly diagnosed LC pts in 2020 were more likely to be diagnosed with stage IV disease. The Italian Oncology Departments ensured the maintenance of the diagnostic-therapeutic pathways of LC pts. A reverse migration from high-volume to low-volume cancer centers was noted during the pandemic.
Collapse
Affiliation(s)
- L Cantini
- Department of Medical Oncology, Università Politecnica delle Marche, AOU Ospedali Riuniti di Ancona, Ancona, Italy. https://twitter.com/LucaCantiniMD
| | - G Mentrasti
- Department of Medical Oncology, Università Politecnica delle Marche, AOU Ospedali Riuniti di Ancona, Ancona, Italy
| | - G L Russo
- Oncologia Medica 1, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy
| | - D Signorelli
- Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy
| | - G Pasello
- Department of Surgery, Oncology and Gastroenterology, University of Padova, Padua, Italy; Medical Oncology 2, Istituto Oncologico Veneto IRCCS, Padua, Italy
| | - E Rijavec
- Medical Oncology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
| | - M Russano
- Department of Medical Oncology, Campus Bio-Medico University, Rome, Italy
| | - L Antonuzzo
- Medical Oncology Unit, Careggi University Hospital, Florence, Italy
| | - D Rocco
- Department of Pulmonology and Oncology, AORN dei Colli Monaldi, Naples, Italy
| | - R Giusti
- UOC Oncologia Medica, Azienda Ospedaliero Universitaria Sant'Andrea, Università La Sapienza, Rome, Italy
| | - V Adamo
- Oncologia Medica, A.O.Papardo & Università di Messina, Messina, Italy
| | - C Genova
- UOC Clinica di Oncologia Medica, IRCCS Ospedale San Martino, Department of Internal Medicine and Medical Specialties (DIMI), Università degli Studi di Genova, Genoa, Italy
| | - A Tuzi
- Oncologia Medica, ASST Sette Laghi, Varese, Italy
| | - A Morabito
- Thoracic Medical Oncology, Istituto Nazionale Tumori "Fondazione G Pascale", IRCCS, Naples, Italy
| | - S Gori
- UOC Oncologia Medica, IRCCS Ospedale Sacro Cuore Don Calabria, Negrar di Valpolicella, Verona, Italy
| | - N La Verde
- Department of Oncology, Ospedale Luigi Sacco, ASST Fatebenefratelli Sacco, Milan, Italy
| | - R Chiari
- Medical Oncology, Ospedali Riuniti Padova Sud, Monselice, Italy
| | - A Cortellini
- Medical Oncology, St Salvatore Hospital, L'Aquila, Italy
| | - V Cognigni
- Department of Medical Oncology, Università Politecnica delle Marche, AOU Ospedali Riuniti di Ancona, Ancona, Italy
| | - F Pecci
- Department of Medical Oncology, Università Politecnica delle Marche, AOU Ospedali Riuniti di Ancona, Ancona, Italy
| | - A Indini
- Medical Oncology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
| | - A De Toma
- Oncologia Medica 1, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy
| | - E Zattarin
- Oncologia Medica 1, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy
| | - S Oresti
- Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy; Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy
| | - E G Pizzutilo
- Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy; Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy
| | - S Frega
- Medical Oncology 2, Istituto Oncologico Veneto IRCCS, Padua, Italy
| | - E Erbetta
- Medical Oncology 2, Istituto Oncologico Veneto IRCCS, Padua, Italy
| | - A Galletti
- Department of Medical Oncology, Campus Bio-Medico University, Rome, Italy
| | - F Citarella
- Department of Medical Oncology, Campus Bio-Medico University, Rome, Italy
| | - S Fancelli
- Medical Oncology Unit, Careggi University Hospital, Florence, Italy
| | - E Caliman
- Medical Oncology Unit, Careggi University Hospital, Florence, Italy
| | - L Della Gravara
- Dipartment of Experimental Medicine, Università degli Studi della Campania "Luigi Vanvitelli", Naples, Italy
| | - U Malapelle
- Department of Public Health, Università degli Studi di Napoli "Federico II", Naples, Italy
| | - M Filetti
- UOC Oncologia Medica, Azienda Ospedaliero Universitaria Sant'Andrea, Università La Sapienza, Rome, Italy
| | - M Piras
- UOC Oncologia Medica, Azienda Ospedaliero Universitaria Sant'Andrea, Università La Sapienza, Rome, Italy
| | - G Toscano
- Oncologia Medica, A.O.Papardo, Messina, Italy
| | - L Zullo
- UOC Oncologia Medica 2, IRCCS Ospedale San Martino, Genoa, Italy
| | - M De Tursi
- Department of Innovative Technologies in Medicine & Dentistry, Università G. D'Annunzio, Chieti-Pescara, Chieti, Italy
| | - P Di Marino
- Department of Innovative Technologies in Medicine & Dentistry, Università G. D'Annunzio, Chieti-Pescara, Chieti, Italy
| | - V D'Emilio
- UOC Pneumologia, Ospedale Mazzoni, Ascoli Piceno, Italy
| | - M S Cona
- Department of Oncology, Ospedale Luigi Sacco, ASST Fatebenefratelli Sacco, Milan, Italy
| | - A Guida
- Oncologia Medica e Traslazionale, AO Santa Maria, Terni, Italy
| | - A Caglio
- Department of Oncology, University of Turin, Ordine Mauriziano Hospital, Turin, Italy
| | - F Salerno
- Department of Oncology, University of Turin, Ordine Mauriziano Hospital, Turin, Italy
| | - G Spinelli
- UOC Territorial Oncology, University "Sapienza", AUSL Latina, Cds Aprilia, Aprilia, Italy
| | - C Bennati
- Department of Onco-Hematology, AUSL della Romagna, Ravenna, Italy
| | - F Morgillo
- UOC Oncologia ed Ematologia, Department of Precision Medicine, Università degli studi della Campania "Luigi Vanvitelli", Naples, Italy
| | - A Russo
- Oncologia Medica, A.O.Papardo, Messina, Italy
| | - C Dellepiane
- UOC Oncologia Medica 2, IRCCS Ospedale San Martino, Genoa, Italy
| | - I Vallini
- Oncologia Medica, ASST Sette Laghi, Varese, Italy
| | - V Sforza
- Thoracic Medical Oncology, Istituto Nazionale Tumori "Fondazione G Pascale", IRCCS, Naples, Italy
| | - A Inno
- UOC Oncologia Medica, IRCCS Ospedale Sacro Cuore Don Calabria, Negrar di Valpolicella, Verona, Italy
| | - F Rastelli
- UOC Oncologia, Ospedale Mazzoni, Ascoli Piceno, Italy
| | - V Tassi
- Chirurgia Toracica, AO Santa Maria, Terni, Italy
| | - L Nicolardi
- Medical Oncology, Ospedali Riuniti Padova Sud, Monselice, Italy
| | - V Pensieri
- Medical Oncology, St Salvatore Hospital, L'Aquila, Italy
| | - R Emili
- Operative Oncology Unit, Azienda Ospedaliera Ospedali Riuniti Marche Nord, Pesaro, Italy
| | - E Roca
- Thoracic Oncology - Lung Unit, Pederzoli Hospital, Peschiera Del Garda, Italy
| | - A Migliore
- Department of Medical Oncology, Università Politecnica delle Marche, AOU Ospedali Riuniti di Ancona, Ancona, Italy
| | - T Galassi
- Department of Medical Oncology, Università Politecnica delle Marche, AOU Ospedali Riuniti di Ancona, Ancona, Italy
| | - M L Bruno Rocchi
- Biomolecular Sciences Department, University of Urbino, Urbino, Italy
| | - R Berardi
- Department of Medical Oncology, Università Politecnica delle Marche, AOU Ospedali Riuniti di Ancona, Ancona, Italy.
| |
Collapse
|
7
|
Roca E, Lombardi C. Covid-19: less bronchial airways, more lung alveolar space and blood ways. Eur Ann Allergy Clin Immunol 2021; 53:243-244. [PMID: 33944543 DOI: 10.23822/eurannaci.1764-1489.205] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Affiliation(s)
- E Roca
- Covid-19 Unit, Poliambulanza Foundation Hospital, Brescia, Italy.,Technology for Health, PhD program, University of Brescia, Brescia, Italy
| | - C Lombardi
- Departmental Unit of Pulmonary and Allergic Respiratory Diseases, Poliambulanza Foundation Hospital, Brescia, Italy
| |
Collapse
|
8
|
Zanoletti E, Mazzoni A, Martini A, Abbritti RV, Albertini R, Alexandre E, Baro V, Bartolini S, Bernardeschi D, Bivona R, Bonali M, Borghesi I, Borsetto D, Bovo R, Breun M, Calbucci F, Carlson ML, Caruso A, Cayé-Thomasen P, Cazzador D, Champagne PO, Colangeli R, Conte G, D'Avella D, Danesi G, Deantonio L, Denaro L, Di Berardino F, Draghi R, Ebner FH, Favaretto N, Ferri G, Fioravanti A, Froelich S, Giannuzzi A, Girasoli L, Grossardt BR, Guidi M, Hagen R, Hanakita S, Hardy DG, Iglesias VC, Jefferies S, Jia H, Kalamarides M, Kanaan IN, Krengli M, Landi A, Lauda L, Lepera D, Lieber S, Lloyd SLK, Lovato A, Maccarrone F, Macfarlane R, Magnan J, Magnoni L, Marchioni D, Marinelli JP, Marioni G, Mastronardi V, Matthies C, Moffat DA, Munari S, Nardone M, Pareschi R, Pavone C, Piccirillo E, Piras G, Presutti L, Restivo G, Reznitsky M, Roca E, Russo A, Sanna M, Sartori L, Scheich M, Shehata-Dieler W, Soloperto D, Sorrentino F, Sterkers O, Taibah A, Tatagiba M, Tealdo G, Vlad D, Wu H, Zanetti D. Surgery of the lateral skull base: a 50-year endeavour. ACTA ACUST UNITED AC 2019; 39:S1-S146. [PMID: 31130732 PMCID: PMC6540636 DOI: 10.14639/0392-100x-suppl.1-39-2019] [Citation(s) in RCA: 60] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
Disregarding the widely used division of skull base into anterior and lateral, since the skull base should be conceived as a single anatomic structure, it was to our convenience to group all those approaches that run from the antero-lateral, pure lateral and postero-lateral side of the skull base as “Surgery of the lateral skull base”. “50 years of endeavour” points to the great effort which has been made over the last decades, when more and more difficult surgeries were performed by reducing morbidity. The principle of lateral skull base surgery, “remove skull base bone to approach the base itself and the adjacent sites of the endo-esocranium”, was then combined with function preservation and with tailoring surgery to the pathology. The concept that histology dictates the extent of resection, balancing the intrinsic morbidity of each approach was the object of the first section of the present report. The main surgical approaches were described in the second section and were conceived not as a step-by-step description of technique, but as the highlighthening of the surgical principles. The third section was centered on open issues related to the tumor and its treatment. The topic of vestibular schwannoma was investigated with the current debate on observation, hearing preservation surgery, hearing rehabilitation, radiotherapy and the recent efforts to detect biological markers able to predict tumor growth. Jugular foramen paragangliomas were treated in the frame of radical or partial surgery, radiotherapy, partial “tailored” surgery and observation. Surgery on meningioma was debated from the point of view of the neurosurgeon and of the otologist. Endolymphatic sac tumors and malignant tumors of the external auditory canal were also treated, as well as chordomas, chondrosarcomas and petrous bone cholesteatomas. Finally, the fourth section focused on free-choice topics which were assigned to aknowledged experts. The aim of this work was attempting to report the state of the art of the lateral skull base surgery after 50 years of hard work and, above all, to raise questions on those issues which still need an answer, as to allow progress in knowledge through sharing of various experiences. At the end of the reading, if more doubts remain rather than certainties, the aim of this work will probably be achieved.
Collapse
Affiliation(s)
- E Zanoletti
- Department of Neuroscience DNS, Otolaryngology Section, Padova University, Padova, Italy
| | - A Mazzoni
- Department of Neuroscience DNS, Otolaryngology Section, Padova University, Padova, Italy
| | - A Martini
- Department of Neuroscience DNS, Otolaryngology Section, Padova University, Padova, Italy
| | - R V Abbritti
- Department of Neurosurgery, Lariboisière Hospital, University of Paris Diderot, Paris, France
| | | | - E Alexandre
- Department of Neuroscience DNS, Otolaryngology Section, Padova University, Padova, Italy
| | - V Baro
- Academic Neurosurgery, Department of Neuroscience DNS, University of Padova Medical School, Padova, Italy
| | - S Bartolini
- Neurosurgery, Bellaria Hospital, Bologna, Italy
| | - D Bernardeschi
- AP-HP, Groupe Hôspital-Universitaire Pitié-Salpêtrière, Neuro-Sensory Surgical Department and NF2 Rare Disease Centre, Paris, France.,Sorbonne Université, Paris, France
| | - R Bivona
- ENT and Skull-Base Surgery Department, Department of Neurosciences, Ospedale Papa Giovanni XXIII, Bergamo, Italy
| | - M Bonali
- Otolaryngology-Head and Neck Surgery Department, University Hospital of Modena, Italy
| | - I Borghesi
- Neurosurgery, Maria Cecilia Hospital, Cotignola (RA), Italy
| | - D Borsetto
- Department of Neuroscience DNS, Otolaryngology Section, Padova University, Padova, Italy
| | - R Bovo
- Department of Neuroscience DNS, Otolaryngology Section, Padova University, Padova, Italy
| | - M Breun
- Department of Neurosurgery, Julius Maximilians University Hospital Würzburg, Bavaria, Germany
| | - F Calbucci
- Neurosurgery, Maria Cecilia Hospital, Cotignola (RA), Italy
| | - M L Carlson
- Department of Otolaryngology-Head and Neck Surgery, Mayo Clinic, Rochester, MN, USA.,Department of Neurologic Surgery, Mayo Clinic, Rochester, MN, USA
| | - A Caruso
- Gruppo Otologico, Piacenza-Rome, Italy
| | - P Cayé-Thomasen
- The Department of Otorhinolaryngology, Head & Neck Surgery and Audiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.,Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
| | - D Cazzador
- Department of Neuroscience DNS, Otolaryngology Section, Padova University, Padova, Italy.,Department of Neuroscience DNS, Section of Human Anatomy, Padova University, Padova, Italy
| | - P-O Champagne
- Department of Neurosurgery, Lariboisière Hospital, University of Paris Diderot, Paris, France
| | - R Colangeli
- Department of Neuroscience DNS, Otolaryngology Section, Padova University, Padova, Italy
| | - G Conte
- Department of Neuroradiology, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milano, Italy
| | - D D'Avella
- Academic Neurosurgery, Department of Neuroscience DNS, University of Padova Medical School, Padova, Italy
| | - G Danesi
- ENT and Skull-Base Surgery Department, Department of Neurosciences, Ospedale Papa Giovanni XXIII, Bergamo, Italy
| | - L Deantonio
- Department of Radiation Oncology, University Hospital Maggiore della Carità, Novara, Italy.,Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy
| | - L Denaro
- Academic Neurosurgery, Department of Neuroscience DNS, University of Padova Medical School, Padova, Italy
| | - F Di Berardino
- Unit of Audiology, Department of Clinical Sciences and Community Health, University of Milano, Italy.,Department of Surgery, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milano, Italy
| | - R Draghi
- Neurosurgery, Maria Cecilia Hospital, Cotignola (RA), Italy
| | - F H Ebner
- Department of Neurosurgery, Eberhard Karls University Tübingen, Germany
| | - N Favaretto
- Department of Neuroscience DNS, Otolaryngology Section, Padova University, Padova, Italy
| | - G Ferri
- Otolaryngology-Head and Neck Surgery Department, University Hospital of Modena, Italy
| | | | - S Froelich
- Department of Neurosurgery, Lariboisière Hospital, University of Paris Diderot, Paris, France
| | | | - L Girasoli
- Department of Neuroscience DNS, Otolaryngology Section, Padova University, Padova, Italy
| | - B R Grossardt
- Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA
| | - M Guidi
- Gruppo Otologico, Piacenza-Rome, Italy
| | - R Hagen
- Department of Otorhinolaryngology, Plastic, Aesthetic and Reconstructive Head and Neck Surgery, "Julius-Maximilians" University Hospital of Würzburg, Bavaria, Germany
| | - S Hanakita
- Department of Neurosurgery, Lariboisière Hospital, University of Paris Diderot, Paris, France
| | - D G Hardy
- Department of Neurosurgery, Cambridge University Hospital, Cambridge, UK
| | - V C Iglesias
- ENT and Skull-Base Surgery Department, Department of Neurosciences, Ospedale Papa Giovanni XXIII, Bergamo, Italy
| | - S Jefferies
- Oncology Department, Cambridge University Hospital, Cambridge, UK
| | - H Jia
- Department of Otolaryngology Head and Neck Surgery, Shanghai Ninh People's Hospital, Shanghai Jiatong University School of Medicine, China
| | - M Kalamarides
- AP-HP, Groupe Hôspital-Universitaire Pitié-Salpêtrière, Neuro-Sensory Surgical Department and NF2 Rare Disease Centre, Paris, France.,Sorbonne Université, Paris, France
| | - I N Kanaan
- Department of Neurosciences, King Faisal Specialist Hospital & Research Center, Alfaisal University, College of Medicine, Riyadh, KSA
| | - M Krengli
- Department of Radiation Oncology, University Hospital Maggiore della Carità, Novara, Italy.,Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy
| | - A Landi
- Academic Neurosurgery, Department of Neuroscience DNS, University of Padova Medical School, Padova, Italy
| | - L Lauda
- Gruppo Otologico, Piacenza-Rome, Italy
| | - D Lepera
- ENT & Skull-Base Department, Ospedale Nuovo di Legnano, Legnano (MI), Italy
| | - S Lieber
- Department of Neurosurgery, Eberhard Karls University Tübingen, Germany
| | - S L K Lloyd
- Department of Neuro-Otology and Skull-Base Surgery Manchester Royal Infirmary, Manchester, UK
| | - A Lovato
- Department of Neuroscience DNS, Audiology Unit, Padova University, Treviso, Italy
| | - F Maccarrone
- Otolaryngology-Head and Neck Surgery Department, University Hospital of Modena, Italy
| | - R Macfarlane
- Department of Neurosurgery, Cambridge University Hospital, Cambridge, UK
| | - J Magnan
- University Aix-Marseille, France
| | - L Magnoni
- Unit of Audiology, Department of Clinical Sciences and Community Health, University of Milano, Italy.,Department of Surgery, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milano, Italy
| | - D Marchioni
- Otolaryngology-Head and Neck Surgery Department, University Hospital of Verona, Italy
| | | | - G Marioni
- Department of Neuroscience DNS, Otolaryngology Section, Padova University, Padova, Italy
| | | | - C Matthies
- Department of Neurosurgery, Julius Maximilians University Hospital Würzburg, Bavaria, Germany
| | - D A Moffat
- Department of Neuro-otology and Skull Base Surgery, Cambridge University Hospital, Cambridge, UK
| | - S Munari
- Department of Neuroscience DNS, Otolaryngology Section, Padova University, Padova, Italy
| | - M Nardone
- ENT Department, Treviglio (BG), Italy
| | - R Pareschi
- ENT & Skull-Base Department, Ospedale Nuovo di Legnano, Legnano (MI), Italy
| | - C Pavone
- Department of Neuroscience DNS, Otolaryngology Section, Padova University, Padova, Italy
| | | | - G Piras
- Gruppo Otologico, Piacenza-Rome, Italy
| | - L Presutti
- Otolaryngology-Head and Neck Surgery Department, University Hospital of Modena, Italy
| | - G Restivo
- ENT and Skull-Base Surgery Department, Department of Neurosciences, Ospedale Papa Giovanni XXIII, Bergamo, Italy
| | - M Reznitsky
- The Department of Otorhinolaryngology, Head & Neck Surgery and Audiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
| | - E Roca
- Department of Neurosurgery, Lariboisière Hospital, University of Paris Diderot, Paris, France
| | - A Russo
- Gruppo Otologico, Piacenza-Rome, Italy
| | - M Sanna
- Gruppo Otologico, Piacenza-Rome, Italy
| | - L Sartori
- Academic Neurosurgery, Department of Neuroscience DNS, University of Padova Medical School, Padova, Italy
| | - M Scheich
- Department of Otorhinolaryngology, Plastic, Aesthetic and Reconstructive Head and Neck Surgery, "Julius-Maximilians" University Hospital of Würzburg, Bavaria, Germany
| | - W Shehata-Dieler
- Department of Otorhinolaryngology, Plastic, Aesthetic and Reconstructive Head and Neck Surgery, "Julius-Maximilians" University Hospital of Würzburg, Bavaria, Germany
| | - D Soloperto
- Otolaryngology-Head and Neck Surgery Department, University Hospital of Verona, Italy
| | - F Sorrentino
- Department of Neuroscience DNS, Otolaryngology Section, Padova University, Padova, Italy
| | - O Sterkers
- AP-HP, Groupe Hôspital-Universitaire Pitié-Salpêtrière, Neuro-Sensory Surgical Department and NF2 Rare Disease Centre, Paris, France.,Sorbonne Université, Paris, France
| | - A Taibah
- Gruppo Otologico, Piacenza-Rome, Italy
| | - M Tatagiba
- Department of Neurosurgery, Eberhard Karls University Tübingen, Germany
| | - G Tealdo
- Department of Neuroscience DNS, Otolaryngology Section, Padova University, Padova, Italy
| | - D Vlad
- Gruppo Otologico, Piacenza-Rome, Italy
| | - H Wu
- Department of Otolaryngology Head and Neck Surgery, Shanghai Ninh People's Hospital, Shanghai Jiatong University School of Medicine, China
| | - D Zanetti
- Unit of Audiology, Department of Clinical Sciences and Community Health, University of Milano, Italy.,Department of Surgery, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milano, Italy
| |
Collapse
|
9
|
Grasselli J, Rizzolo M, Ruiz G, Salanova R, Mariani J, O’Connor J, Luca R, Cabanne A, Mendez G, Roca E. Gastroenteropancreatic neuroendocrine neoplasia G3 according to 2019 WHO classification: a comprehensive clinicopathological characterization including mismatch repair proteins and PDL1 expression in a large cohort of patients. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz155.094] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
10
|
Iseas S, Coraglio M, Gonzalez J, Slutsky E, Carvajal D, Cabanne A, Carballido M, Mendez G, Picconi M, Roca E. Prevalence and genotyping of HPV in anal squamous cell carcinoma. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy151.111] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
11
|
Cazap E, Estevez R, Bruno M, Levy D, Algamiz C, Chacon R, Badano C, Romero A, Desimone G, Roca E. Phase II Trial of 4′-Epi-Doxorubicin in Locally Advanced or Metastatic Gastric Cancer. Tumori 2018; 74:313-5. [PMID: 3165228 DOI: 10.1177/030089168807400312] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Patients with locally advanced or metastatic gastric adenocarcinoma received an i.v. bolus of 4′-epi-doxorubicin, 75/mg/m2/cycle, every 21 days. Partial responses were observed in 5 of 23 evaluable patients (21.7%). Treatment was generally well tolerated and toxicity was mild. The response rate to epirubicin appears to be very similar to that reported for doxorubicin. Larger doses of epirubicin could be safely used in future studies, and further evaluation of epirubicin in phase III trials is indicated.
Collapse
Affiliation(s)
- E Cazap
- Grupo Argentino de Tratamiento de los Tumores Sólidos (GATTS), Buenos Aires, Argentina
| | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Passos F, Roca E, Castro-López R, Fernández F. Radio-frequency inductor synthesis using evolutionary computation and Gaussian-process surrogate modeling. Appl Soft Comput 2017. [DOI: 10.1016/j.asoc.2017.07.036] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
13
|
Mazziotti G, Formenti AM, Frara S, Roca E, Mortini P, Berruti A, Giustina A. MANAGEMENT OF ENDOCRINE DISEASE: Risk of overtreatment in patients with adrenal insufficiency: current and emerging aspects. Eur J Endocrinol 2017; 177:R231-R248. [PMID: 28583942 DOI: 10.1530/eje-17-0154] [Citation(s) in RCA: 51] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/22/2017] [Revised: 05/31/2017] [Accepted: 06/05/2017] [Indexed: 01/17/2023]
Abstract
The effects of long-term replacement therapy of adrenal insufficiency (AI) are still a matter of controversy. In fact, the established glucocorticoid replacement regimens do not completely reproduce the endogenous hormonal production and the monitoring of AI treatment may be a challenge for the lack of reliable clinical and biochemical markers. Consequently, several AI patients are frequently exposed to relative glucocorticoid excess potentially leading to develop chronic complications, such as diabetes mellitus, dyslipidemia, hypertension and fragility fractures with consequent impaired QoL and increased mortality risk. This review deals with the pathophysiological and clinical aspects concerning the over-replacement therapy of primary and secondary AI.
Collapse
Affiliation(s)
- G Mazziotti
- Endocrinology Unit, ASST, Carlo Poma, Mantua, Italy
| | - A M Formenti
- Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy
| | - S Frara
- Chair of Endocrinology, San Raffaele Vita-Salute University, Milan, Italy
| | - E Roca
- Chair of Medical Oncology, University of Brescia, Brescia, Italy
| | - P Mortini
- Chair of Neurosurgery, San Raffaele Vita-Salute University, Milan, Italy
| | - A Berruti
- Chair of Medical Oncology, University of Brescia, Brescia, Italy
| | - A Giustina
- Chair of Endocrinology, San Raffaele Vita-Salute University, Milan, Italy
| |
Collapse
|
14
|
Passaro A, Metro G, Tiseo M, Migliorino M, Santo A, Sperandi F, Maione P, Puppo G, Grossi F, Soto Parra H, Borra G, Roca E, Rocco D, Stasi I, Galetta D, Carta A, Milella M, Fasola G, Gebbia V, Ferrari S, De Marinis F. ASTRIS, a real world treatment study of osimertinib in patients (pts) with EGFR T790M positive non-small cell lung cancer (NSCLC): preliminary analysis of the Italian cohort. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx426.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
15
|
Borghetti P, Bonù M, Roca E, Salah E, Baiguini A, Pedretti S, Maddalo M, Buglione M, Magrini S. EP-1219: Concomitant radiotherapy and TKI in EGFR mutant or ALK positive stage IV non-small cell lung cancer. Radiother Oncol 2017. [DOI: 10.1016/s0167-8140(17)31654-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
16
|
Iseas S, Coraglio M, Dieguez A, Eleta M, Bertoncini C, Tejerina H, Carballido M, Bianchi R, Leiro F, Mendez G, Barugel M, Roca E. P-127 Pathological versus clinical complete responders after preoperative treatment in rectal cancer: long term outcomes analysis. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw199.121] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
17
|
Gaston AF, Roca E, Doucende G, Hapkova I, Subirats E, Durand F. Réponses physiologiques à l’exercice en altitude modérée : intérêt de la mesure de la SpO2. Sci Sports 2016. [DOI: 10.1016/j.scispo.2015.06.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
18
|
Fontanella MM, Panciani PP, Spena G, Roca E, Migliorati K, Ambrosi C, Sturiale CL, Retta SF. Professional athletes and cerebral cavernomas: an obstacle to overcome. J Sports Med Phys Fitness 2015; 55:1046-1047. [PMID: 24637509] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Affiliation(s)
- M M Fontanella
- Department of Neurosurgery, University of Brescia, Brescia, Italy -
| | | | | | | | | | | | | | | |
Collapse
|
19
|
Roca E, Mendez C, Ruiz J. J04 Individualised Nutritional Intervention to Avoid Weight Loss in HD Patients during Hospitalisation. J Neurol Psychiatry 2014. [DOI: 10.1136/jnnp-2014-309032.187] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
20
|
Astoul P, Roca E, Galateau-Salle F, Scherpereel A. Malignant Pleural Mesothelioma: From the Bench to the Bedside. Respiration 2012; 83:481-93. [DOI: 10.1159/000339259] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
|
21
|
Rodriguez Espíndola A, Chacon M, Eleta M, Roca E, Mendez G, Rojo S, Puparelli C, Chacon R. Assessment of early response to imatinib 800 mg after 400 mg progression by 18f-fluorodeoxyglucose positron emission tomography in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.10081] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
22
|
Franco-Uría A, Otero-Muras I, Balsa-Canto E, Alonso AA, Roca E. Generic parameterization for a pharmacokinetic model to predict Cd concentrations in several tissues of different fish species. Chemosphere 2010; 79:377-386. [PMID: 20202672 DOI: 10.1016/j.chemosphere.2010.02.010] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/24/2009] [Revised: 02/03/2010] [Accepted: 02/03/2010] [Indexed: 05/28/2023]
Abstract
In the present work, a set of generic parameters was proposed for a pharmacokinetic model, with the objective of predicting Cd concentration in the tissues of diverse fish species under different environmental conditions. Cd concentrations in a number of tissues of Oncorhynchus mykiss and Cyprinus carpio were estimated by a structurally identifiable multicompartmental model (unique solution). The 13 generic parameters of the model comprised exchange rates, tissue-blood partition coefficients, and weight-corrected elimination rate constants accounting for the routes of water respiration, excretion and egestion. On the other hand, absorption efficiencies from water and food were considered to be condition-specific and estimated for each experiment. These two parameters reflected the differences in fish exposure to diet (food type and metal concentration) or water (water chemistry and bioavailable metal concentration). A data set of 27 experiments of Cd bioaccumulation in fish tissues was compiled for model calibration. The selected dynamics on trout and carp were performed under very different experimental conditions, involving water and/or food exposure, different fish weights and exposure concentrations and the presence/absence of depuration periods. Model predicted, for most compartments and experiments, the tendency of Cd dynamics. However, accumulation in liver and kidney was underestimated in approximately a half of the experiments, due mainly to a rapid metallothionein (MT) sequestration phenomena and subsequent saturation on liver and kidney produced under high exposure concentrations. On the other hand, both generic and condition-specific parameter values were in accordance with the values reported in literature when available. Therefore, the results obtained in this work are an initial step indicating that a generic global input parameter set could be applied to physiology-based pharmacokinetic (PBPK) models for estimating Cd accumulation in fish in different types of scenarios.
Collapse
Affiliation(s)
- A Franco-Uría
- Process Engineering Group, Marine Research Institute IIM-CSIC, Eduardo Cabello 6, 36208 Vigo, Spain.
| | | | | | | | | |
Collapse
|
23
|
Zamora V, Cabanne A, Salanova R, Bestani C, Domenichini E, Marmissolle F, Giacomi N, O'Connor J, Méndez G, Roca E. Immunohistochemical expression of somatostatin receptors in digestive endocrine tumours. Dig Liver Dis 2010; 42:220-5. [PMID: 19819769 DOI: 10.1016/j.dld.2009.07.018] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/18/2009] [Revised: 06/30/2009] [Accepted: 07/28/2009] [Indexed: 12/11/2022]
Abstract
INTRODUCTION Somatostatin receptors are expressed in a large number of human tumours. The somatostatin receptors types 1-5 expression in a series including 100 gastro-entero-pancreatic endocrine tumours were analysed. METHODS From a prospectively built database of patients with gastro-entero-pancreatic endocrine tumours referred from three institutions, 100 cases with clinical and pathological data were selected. Somatostatin receptors expression by immunohistochemistry with somatostatin receptor types 1-5 antibodies in tissue paraffin sections were studied and correlated with the histological diagnosis according to the WHO classification, location and functional status. RESULTS Of the 100 cases, 67 were gastrointestinal tumours, 25 pancreatic and 8 liver metastasis of unknown origin. Thirty-one of them were functioning tumours: 2 insulinomas, 5 gastrinomas, 1 glucagonoma and 23 carcinoids. Somatostatin receptors expression was observed in 94 tumours. The six negative cases were all non-functioning tumours. Somatostatin receptors 2a and 5 were highly expressed (86 and 62%, respectively), and surprisingly found even in poorly differentiated endocrine carcinomas. Somatostatin receptors expression was less frequent in pancreatic than in gastrointestinal tumours. Well-differentiated neoplasms had a higher density of somatostatin receptors. Only SSTR2a showed membrane staining. CONCLUSIONS Immunohistochemistry revealed that somatostatin receptors were highly expressed in both primary and metastatic gastro-entero-pancreatic endocrine tumours with heterogeneous staining distribution. It proved to be a reliable technique even in small tumour samples.
Collapse
Affiliation(s)
- V Zamora
- Gastroenterology Hospital "C. Bonorino Udaondo", Buenos Aires, Argentina
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Campos JL, Otero L, Franco A, Mosquera-Corral A, Roca E. Ozonation strategies to reduce sludge production of a seafood industry WWTP. Bioresour Technol 2009; 100:1069-1073. [PMID: 18835774 DOI: 10.1016/j.biortech.2008.07.056] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/22/2008] [Revised: 07/24/2008] [Accepted: 07/29/2008] [Indexed: 05/26/2023]
Abstract
In this work, several alternatives related to the application of ozone in different streams of a seafood industry WWTP were evaluated to minimize the production of waste sludge. The WWTP was composed of two coagulation-flocculation units and a biological unit and generated around of 6550 kg/d of sludge. Ozone was applied to sludge coming from flotation units (110 g TSS/L) at doses up to 0.03 g O(3)/g TSS during batch tests, no solids solubilization being observed. Ozone doses ranging from 0.007 to 0.02 g O(3)/g TSS were also applied to the raw wastewater in a bubble column reaching a 6.8% of TSS removal for the highest ozone dose. Finally, the effect of the pre-ozonation (0.05 g O(3)/g TSS) of wastewater coming from the first flotation unit was tested in two activated sludge systems during 70 days. Ozonation caused a reduction of the observed yield coefficient of biomass from 0.14 to 0.07g TSS/g COD(Tremoved) and a slight improvement of COD removal efficiencies. On the basis of the capacity for ozone production available in the industry, a maximum reduction of sludge generated by the WWTP of 7.5% could be expected.
Collapse
Affiliation(s)
- J L Campos
- Department of Chemical Engineering, School of Engineering, University of Santiago de Compostela, Santiago de Compostela, Spain.
| | | | | | | | | |
Collapse
|
25
|
Molina F, Castellano M, García C, Roca E, Lema JM. Selection of variables for on-line monitoring, diagnosis, and control of anaerobic digestion processes. Water Sci Technol 2009; 60:615-22. [PMID: 19657156 DOI: 10.2166/wst.2009.379] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/16/2023]
Abstract
This work aims to systematize the study of indicators for two types of wastewaters: carbohydrate-based and protein-based synthetic wastewaters. Characterization of steady states and dynamic response analysis against disturbances were carried out using both a factorial discriminant analysis (FDA) and a phenomenological analysis, respectively. This research seeks reconciling both sets of indicators in order to optimize resources and provide a minimal cost in instrumentation for its implementation at industrial scale. According to the results of this research, the best indicators for the two types of wastewaters, considering both process steady states and organic load perturbations are: Biogas flow rate or Methane flow rate, and Hydrogen concentration in the biogas; Volatile fatty acids and Partial alkalinity in the liquid phase.
Collapse
Affiliation(s)
- F Molina
- Department of Chemical Engineering, Universidad de Santiago de Compostela, Spain.
| | | | | | | | | |
Collapse
|
26
|
Herva M, Franco A, Ferreiro S, Alvarez A, Roca E. An approach for the application of the Ecological Footprint as environmental indicator in the textile sector. J Hazard Mater 2008; 156:478-487. [PMID: 18280032 DOI: 10.1016/j.jhazmat.2007.12.077] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/04/2007] [Revised: 12/12/2007] [Accepted: 12/14/2007] [Indexed: 05/25/2023]
Abstract
The Ecological Footprint (EF) is a recent concept which has widely been used as an indicator of environmental sustainability applied to individual lifestyles, regions, nations or even the world. Recently, its application to enterprises has been proposed. In the present study, a textile tailoring plant has been analysed. The overall purpose of this study was to develop a tool useful for evaluating the environmental impact evolution due to the performance of the plant, as well as for comparing the environmental behaviour of different tailoring processes. Therefore, the selected data were those from the manufacturing work. Data were divided in three main categories: energy, resources and waste. The principal contribution to the final EF (expressed in hectares of land) was the resources category, mainly due to the high value associated to the cloth. The consumed energy was the second contributor, while the waste category remained in third place. The final outcomes were divided by the production rates to obtain a comparable relative index, easy to be interpreted by the different stakeholders. This is of special importance for a Company involved in Corporate Social Responsibility and thus meant to have a general communication strategy.
Collapse
Affiliation(s)
- M Herva
- Department of Chemical Engineering, School of Engineering, Lope Gómez de Marzoa s/n, University of Santiago de Compostela, Santiago de Compostela, Spain
| | | | | | | | | |
Collapse
|
27
|
Chacon M, Corless CL, Roca E, Harlow A, Galich M, Le C, Heinrich MC. Molecular epidemiology of gastrointestinal stromal tumors (GISTs): comparison of North and South American patient populations. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.22142] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
28
|
Belli C, Spreafico A, Viganò MG, Lazzari C, Roca E, Villa E, Roder H, Grigorieva J, Tsypin M, Gregorc V. Detection of serum proteomic profile predictive for epidermal growth factor receptor tyrosine kinase inihibitors (EGFR-TKIs) in 1st line chemotherapy responders. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.8091] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
29
|
Alferes J, García-Heras JL, Roca E, García C, Irizar I. Integration of equalisation tanks within control strategies for anaerobic reactors. Validation based on ADM1 simulations. Water Sci Technol 2008; 57:747-752. [PMID: 18401148 DOI: 10.2166/wst.2008.104] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
The combination of equalisation tanks and anaerobic digesters represents a typical design scenario within the treatment of industrial wastewaters. In this context, if the hydraulic capacity of the equalisation tanks is effectively handled, significant improvements in the performance of anaerobic digesters can be achieved in terms of process stability and biogas production. This paper presents a rule-based control strategy for anaerobic reactors with the objective of maximising in the long-term the net production of biogas. The control algorithm combines real-time information about the state of the anaerobic digester with on-line measurements about the wastewater volume of the equalisation tank in order to set permanently the appropriate production of biogas. Such a strategy guarantees a continuous influent flow so that emptying and overflowing episodes in the equalisation tank can be prevented. Aiming at a further full-scale implementation, only reliable and cost-effective on-line instrumentation has been considered within the control architecture. The performance of the proposed control approach has been validated for an anaerobic hybrid configuration (AHR) by simulation using the IWA ADM1 model.
Collapse
Affiliation(s)
- J Alferes
- CEIT and TECNUN. Po de Manuel Lardizabal 15, 20018 San Sebastian, Spain.
| | | | | | | | | |
Collapse
|
30
|
Molina F, García C, Roca E, Lema JM. Characterization of anaerobic granular sludge developed in UASB reactors that treat ethanol, carbohydrates and hydrolyzed protein based wastewaters. Water Sci Technol 2008; 57:837-842. [PMID: 18413942 DOI: 10.2166/wst.2008.067] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
In this work, granules developed from UASB reactors that treat different types of wastewaters (ethanol, carbohydrates and protein-based synthetic wastewaters) were studied. Granule parameters (size distribution; density; settlement characteristics; elemental composition; acidogenic and methanogenic activities) were analyzed along with micro-organisms identified by FISH to better understand granule behavior and its formation process. Micro-organisms distributions in anaerobic granules are highly dependent on the type of treated wastewater. Granules developed in a UASB reactor that treats wastewater with a high content of carbohydrates presented high acidogenic bacteria colonization. Members of Methanosaetaceae were the dominant methanogens in the studied granules, and Methanobacteriales appear to be co-dominant in the granules developed with carbohydrates and protein-based wastewaters.
Collapse
Affiliation(s)
- F Molina
- Department of Chemical Engineering, Universidad de Santiago de Compostela, Rua Lope Gómez de Marzoa s/n, E-15782 Santiago de Compostela, Spain.
| | | | | | | |
Collapse
|
31
|
Barros MC, Bello P, Roca E, Casares JJ. Integrated pollution prevention and control for heavy ceramic industry in Galicia (NW Spain). J Hazard Mater 2007; 141:680-92. [PMID: 16963182 DOI: 10.1016/j.jhazmat.2006.07.037] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/21/2006] [Revised: 07/13/2006] [Accepted: 07/17/2006] [Indexed: 05/11/2023]
Abstract
The heavy ceramic industry (building materials and refractory products manufacture) is an important source of pollutants to the environment. For this reason these industrial sub-sectors are included in prevention and control pollution policies, specifically those of the European Union. The IPPC Directive pays particular attention to the mineral industries, not least to the ceramic industry (epigraph 3.5, Annex I). In this paper, a methodology which is being applied to support IPPC installations and the competent administrative authority in Galicia (NW Spain) is presented. For that, the Galician heavy ceramic industry is analysed, as also are the ways to study the Best Available Techniques (BAT) with a view to establishing the emission limit values (ELV) for each specific case. Hence, a technological state of the art has been carried out for both sub-sectors, from the point of view of implementation of the IPPC in Galicia. Following this, the processes are described briefly and an analysis of the consumption and emission levels of the main pollutants is made. An inventory that includes the best environmental practices and the preventive and abatement candidate techniques as BAT was elaborated for both considered sub-sectors. An information data sheet for each candidate BAT is presented as a method to help both the industries and the competent authority to identify a candidate technique of the inventory as BAT. Three illustrative examples of the application of this procedure are presented for different emissions to environmental media for Galician installations.
Collapse
Affiliation(s)
- M C Barros
- Department of Chemical Engineering, School of Engineering, University of Santiago de Compostela, Rúa Lope Gómez de Marzoa, s/n, E-15782 Santiago de Compostela, Spain
| | | | | | | |
Collapse
|
32
|
Castellano M, Ruiz-Filippi G, González W, Roca E, Lema JM. Selection of variables using factorial discriminant analysis for the state identification of an anaerobic UASB-UAF hybrid pilot plant, fed with winery effluents. Water Sci Technol 2007; 56:139-45. [PMID: 17849988 DOI: 10.2166/wst.2007.482] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/16/2023]
Abstract
Anaerobic wastewater treatment has become a widely used method for wastewater depuration, and has been applied in a wide range of situations, from urban wastewater to highly toxic industrial wastewater. Particularly it has been successfully applied to the treatment of the beverage industries effluents. To avoid the destabilization of the system a monitoring diagnosis and control system of the depuration processes is necessary. The cost of this system is an important issue, that depends on the number of parameters that must be controlled for an adequate performance of a wastewater plant control system. This work shows how the classic statistical classification techniques can be applied to determine the number variables that must be monitored to achieve an adequate performance of anaerobic UASB-UAF hybrid Pilot Plant monitoring and control system. The obtained results had not been unique, so different combinations of variables can be selected for a good wastewater treatment process control. Economic or technical criteria may be considered to determine the final variables set in each particular situation.
Collapse
Affiliation(s)
- M Castellano
- Department of Statistics and O.R., University of Santiago de Compostela, Spain.
| | | | | | | | | |
Collapse
|
33
|
Fernández B, Seijo I, Ruiz-Filippi G, Roca E, Tarenzi L, Lema JM. Characterization, management and treatment of wastewater from white wine production. Water Sci Technol 2007; 56:121-8. [PMID: 17849986 DOI: 10.2166/wst.2007.480] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/17/2023]
Abstract
During a 16 months period, the characteristics of the wastewaters generated in a Rias Baixas winery (Spain) producing white wine were determined: The characterization study showed that white wine wastewater had an average CODt and TSS values of 7.3 and 5.2 kg/m3, respectively being the ratio wastewater/wine produced of about 1.6-2.0 L/L and the ratio between load pollution and produced wine of 9.7 kg(CODt)/m3(WINE). A strategy for the management of wastes and wastewaters allowed for an important reduction of a 55% of wastewater generation to be achieved. In order to select a suitable technology for the treatment of wastewaters two configurations were tested at pilot scale: i) An Anaerobic Filter (AF) of 430 L followed by an activated sludge unit of 510 L and: ii) one activated sludge unit of 510 L. The results showed that the anaerobic/aerobic configuration was more flexible as it adapted quickly to the different loads and flows produced during the different phases through the year. Besides it allowed higher COD removals (98.5-99.2%) to be achieved and proved to permit a quicker re-start up after starvation periods.
Collapse
Affiliation(s)
- B Fernández
- Department of Chemical Engineering, Univ. Santiago de Compostela, Spain.
| | | | | | | | | | | |
Collapse
|
34
|
Molina F, Ruiz-Filippi G, García C, Roca E, Lema JM. Winery effluent treatment at an anaerobic hybrid USBF pilot plant under normal and abnormal operation. Water Sci Technol 2007; 56:25-31. [PMID: 17849974 DOI: 10.2166/wst.2007.468] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/17/2023]
Abstract
A 1.1 m3 hybrid USBF fully instrumented pilot plant has been used for the treatment of diluted wine for four years. In this work, the performance of the wastewater treatment plant (WWTP) during start up and operation (normal operation and overload experiments) is shown. A complete description of the treatment process behaviour (gas and liquid phase composition and anaerobic sludge characteristics) is given by on-line and off-line monitoring of 28 process variables. The results presented here demonstrate the reliability of this technology for the treatment of wastewater from seasonal processes, such as winery wastewaters, during a long period of time (four years). Furthermore, the USBF reactor presented very short start up periods after short and long shut down of the WWTP and rapidly turned back to normal operation after suffering a complete destabilization due to organic overload. Both effluent and biogas were of good quality. Dissolved organic carbon concentration in the effluent was always lower than 100 mg DOC l(-1) under normal operation, while methane concentration in the biogas was in the range 70-74%, making it suitable for energy recovering.
Collapse
Affiliation(s)
- F Molina
- Department of Chemical Engineering, Universidad de Santiago de Compostela, Rua Lope Gómez de Marzoa s/n, E-15782 Santiago de Compostela, Spain.
| | | | | | | | | |
Collapse
|
35
|
Chacon M, Varela M, Huertas E, Roca E, Sanchez Loria F, Kaplan J, Pairola A, O’Connor J, Chacon C, Chacon RD. Surgical salvage of pelvic recurrences from colorectal tumors. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.13580] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
13580 Background: The morbidity of pelvic recurrences from colorectal tumors (PRCT) represents a challenge for the oncology multidisciplinary team. Surgical treatment is the best option for palliation and in several series it offers long term local control in 30% of the cases. Objective: To perform a retrospective analysis of patients (pts) surgically resected for PRCT in terms of: time to progression after surgical salvage (TP) and specific suvival (SS). Correlatives studies were performed with clinic and pathologic factors, surgical procedures (SP), and postoperative complications in terms of TP and SS. Methods: 64 pts treated (June 1994 - February 2005) were identified (women: 30), median age 63 years, site of the primary: rectum 48, sigmoid 16; Median number of resected nodes: 8 (r: 2 - 20) in pts with negative nodes and 15 (r: 6 - 42) in pts with positive nodes; primary treatment: surgery (S): 22 pts, S + chemotherapy (CT): 18, S + radiotherapy (RT): 4, S + CT/RT: 17, CT + S: 2 pts, QT/RT + CX: 1; in 7/64 a Miles procedure was performed as primary therapy, median disease free interval: 15 months; site of initial recurrence: locoregional 58 (90%), locoregional + systemic 10%. Pain and bleeding were the most frecuent symptoms. Results: The strategy in PRCT was: S: 29 pts, S + RT: 15, S + CT/RT: 9, CT/RT + S: 7, S + CT: 2, CT + S: 1, RT + S:1; IORT: 18/64; external beam RT: 17/64, 6 pts required Miles; type of resection: R0: 50/64 (78%), R1: 8/64 (12%), R2: 3/64 (5%) and 3 (5%) unknown. Median duration of surgery: 4 hours, abscesses and fistulas were the complications most frequently observed. Median time to progression (TP): 12 months, site of recurrence (56/64 pts) post salvage surgery: pelvic: 22 pts, extrapelvic: 6 pts, combined: 10 and unknown 18. Eleven pts are free of disease. In 16 pts more than one surgical salvage was perfomed. The specific survival was 21 months (IC 95% 37 - 61 m). Conclusions: In this serie surgical salvage of PRCT showed one year of local control disease, even in pts with R2 and with moderate morbidity. The surgical decision must be individualized and in the context of a trained surgical team. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- M. Chacon
- Fleming, Buenos Aires, Argentina; Instituto Alexander Fleming, Buenos Aires, Argentina
| | - M. Varela
- Fleming, Buenos Aires, Argentina; Instituto Alexander Fleming, Buenos Aires, Argentina
| | - E. Huertas
- Fleming, Buenos Aires, Argentina; Instituto Alexander Fleming, Buenos Aires, Argentina
| | - E. Roca
- Fleming, Buenos Aires, Argentina; Instituto Alexander Fleming, Buenos Aires, Argentina
| | - F. Sanchez Loria
- Fleming, Buenos Aires, Argentina; Instituto Alexander Fleming, Buenos Aires, Argentina
| | - J. Kaplan
- Fleming, Buenos Aires, Argentina; Instituto Alexander Fleming, Buenos Aires, Argentina
| | - A. Pairola
- Fleming, Buenos Aires, Argentina; Instituto Alexander Fleming, Buenos Aires, Argentina
| | - J. O’Connor
- Fleming, Buenos Aires, Argentina; Instituto Alexander Fleming, Buenos Aires, Argentina
| | - C. Chacon
- Fleming, Buenos Aires, Argentina; Instituto Alexander Fleming, Buenos Aires, Argentina
| | - R. D. Chacon
- Fleming, Buenos Aires, Argentina; Instituto Alexander Fleming, Buenos Aires, Argentina
| |
Collapse
|
36
|
O′connor JM, Sade JP, Pairola A, Domenichini E, Cabanne A, Marmisole F, Mendez G, Bestani C, Chacón M, Roca E. Poorly differentiated neuroendocrine carcinoma-small cell of the gastrointestinal tract. Institutional experience. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.14142] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
14142 Background: PDNEC-Small cell (OMS Clasification, grade III)of the GI tract are rare diseases. Small cel represent 0,1% to 1% of all GI malignancies, and are included in the group of PDNEC but: Do these group behave biologically and respond to treatment in the same way? Trying to elucidate this matter, we performed a retrospective analysis of our group of pts. with PDNEC. Methods: A database search was done. from 1997 to 2005 we found 31 pts. with PDNEC/Small cell from the GI Tract treated in our Centers. A review of the clinical records was performed with special interest in response rate and overall survival. interest. Results: 14 pts. were informed by the pathologist at diagnosis PDNEC and 17 pts. as small cell. Median age: 50 years (r 19–84). The most common primary site was Esophagus-Stomach (29%), followed by pancreas 9 pts. (29%. 9 pts.(29%) presented with metastatic disease with unknown orimary Sistemic symptoms were common. A majority of our pts. (61%) presented with overt metastases. The liver was involved in 14 pts. (61%) follow by lymph nodes in 5 (16%). The most common chemotherapy used was a combination Platinum based. Overall response rate was 43%. TTP for all pts were 7 months (95% IC 0.34–0.69). Overall survival was 12 months (95% IC 0,31–0,70). We observed differences in term of overall survival and TTP in favor of PDNEC (15 months vs 10 months and 8 vs 4 months respectively) pNS. Conclusions: PDNEC-Small cell had bad prognosis. In our Serie we found differences between both groups, although not statiscally significant (due to a low number of patients). Definitive data of treatment for the management of this group of pts. still lacks. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- J. M. O′connor
- Instituto Alexander Fleming, Buenos Aires, Argentina; Instituto Fleming, Capital Federal, Argentina; Instituto Fleming, Buenos Airesl, Argentina; Hospital Municipal de Gastroenterología, Capital Federal, Argentina; Breast Clinic, La Plata, Argentina
| | - J. P. Sade
- Instituto Alexander Fleming, Buenos Aires, Argentina; Instituto Fleming, Capital Federal, Argentina; Instituto Fleming, Buenos Airesl, Argentina; Hospital Municipal de Gastroenterología, Capital Federal, Argentina; Breast Clinic, La Plata, Argentina
| | - A. Pairola
- Instituto Alexander Fleming, Buenos Aires, Argentina; Instituto Fleming, Capital Federal, Argentina; Instituto Fleming, Buenos Airesl, Argentina; Hospital Municipal de Gastroenterología, Capital Federal, Argentina; Breast Clinic, La Plata, Argentina
| | - E. Domenichini
- Instituto Alexander Fleming, Buenos Aires, Argentina; Instituto Fleming, Capital Federal, Argentina; Instituto Fleming, Buenos Airesl, Argentina; Hospital Municipal de Gastroenterología, Capital Federal, Argentina; Breast Clinic, La Plata, Argentina
| | - A. Cabanne
- Instituto Alexander Fleming, Buenos Aires, Argentina; Instituto Fleming, Capital Federal, Argentina; Instituto Fleming, Buenos Airesl, Argentina; Hospital Municipal de Gastroenterología, Capital Federal, Argentina; Breast Clinic, La Plata, Argentina
| | - F. Marmisole
- Instituto Alexander Fleming, Buenos Aires, Argentina; Instituto Fleming, Capital Federal, Argentina; Instituto Fleming, Buenos Airesl, Argentina; Hospital Municipal de Gastroenterología, Capital Federal, Argentina; Breast Clinic, La Plata, Argentina
| | - G. Mendez
- Instituto Alexander Fleming, Buenos Aires, Argentina; Instituto Fleming, Capital Federal, Argentina; Instituto Fleming, Buenos Airesl, Argentina; Hospital Municipal de Gastroenterología, Capital Federal, Argentina; Breast Clinic, La Plata, Argentina
| | - C. Bestani
- Instituto Alexander Fleming, Buenos Aires, Argentina; Instituto Fleming, Capital Federal, Argentina; Instituto Fleming, Buenos Airesl, Argentina; Hospital Municipal de Gastroenterología, Capital Federal, Argentina; Breast Clinic, La Plata, Argentina
| | - M. Chacón
- Instituto Alexander Fleming, Buenos Aires, Argentina; Instituto Fleming, Capital Federal, Argentina; Instituto Fleming, Buenos Airesl, Argentina; Hospital Municipal de Gastroenterología, Capital Federal, Argentina; Breast Clinic, La Plata, Argentina
| | - E. Roca
- Instituto Alexander Fleming, Buenos Aires, Argentina; Instituto Fleming, Capital Federal, Argentina; Instituto Fleming, Buenos Airesl, Argentina; Hospital Municipal de Gastroenterología, Capital Federal, Argentina; Breast Clinic, La Plata, Argentina
| |
Collapse
|
37
|
Franco A, Roca E, Lema JM. Granulation in high-load denitrifying upflow sludge bed (USB) pulsed reactors. Water Res 2006; 40:871-80. [PMID: 16497354 DOI: 10.1016/j.watres.2005.11.044] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/31/2005] [Revised: 11/21/2005] [Accepted: 11/27/2005] [Indexed: 05/06/2023]
Abstract
In this work, the effect of the application of a pulse system to anoxic upflow sludge bed (USB) denitrifying reactors for enhancing sludge granulation was studied. In all, three 0.8 L reactors (two operated with flow pulsation, P1 with effluent recycling and P2 without recycling, and one without pulsation and effluent recycling, no pulsation (NP)) were fed with a mixture of NaNO3 and glucose and inoculated with methanogenic granular sludge. The organic loading rate (OLR) and the nitrogen loading rate (NLR) were progressively increased and, at the end of the experiment, extremely high values were obtained (67.5 kgCOD/m3d and 11.25 kgN-NO3-/m3 d). Ammonia and nitrite accumulation in reactor NP were important in the maturation stage, decreasing the denitrification efficiency to 90%, while in reactor P1 only low nitrite values were obtained in the last few days of the experiment. In reactor P2, nitrogen removal was 100% most of the time. Several operational problems (flotation and the subsequent wash out of biomass) appeared in the NP reactor when working at high denitrifying loading rates, while in reactors P1 and P2 there were no notable problems, mainly due to the good characteristics of the sludge developed and the efficient degasification produced by the pulsing flow. The sludge formed in the NP reactor presented a flocculent structure and a total disintegration of the initial methanogenic granules occurred, while a small-sized granular biomass with a high specific density was developed in the pulsed reactors due to the shear stress produced.
Collapse
Affiliation(s)
- A Franco
- Department of Chemical Engineering, Institute of Technology, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | | | | |
Collapse
|
38
|
Rodríguez J, Ruiz G, Molina F, Roca E, Lema JM. A hydrogen-based variable-gain controller for anaerobic digestion processes. Water Sci Technol 2006; 54:57-62. [PMID: 16939084 DOI: 10.2166/wst.2006.486] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/11/2023]
Abstract
An easy-to-implement controller based on gas phase measurements for anaerobic digestion processes was developed. The controller is based on the indirect control of COD in the effluent by means of controlling the hydrogen concentration in the biogas. The fast response of hydrogen under destabilizations, such as those caused by overloads, guarantees an early actuation on the system before it destabilizes. The controller is designed such that it brings the anaerobic digestion process to maximum capacity by pushing it to maximum methane production as long as hydrogen remains low. Experiments have been conducted to test the controller under organic over- and underload situations and promising performance was achieved. Further experiments must be carried out to validate the controller under a wider spectrum of situations to enable its robust industrial application.
Collapse
Affiliation(s)
- J Rodríguez
- Department of Chemical Engineering, School of Engineering, Universidade de Santiago de Compostela, Spain.
| | | | | | | | | |
Collapse
|
39
|
Szyldergemajn SA, O’Connor J, Mendez G, Chacón M, Barugel M, Marmissolle F, Amat M, Domenichini E, Roca E. Neuroendocrine tumors of the gastroenteropancreatic system (NET-GEP). Correlation between Ki-67 immunostaining, histological features and clinical behaviour. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.4192] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- S. A. Szyldergemajn
- Hosp Udaondo, Buenos Aires, Argentina; Inst Alexander Fleming, Buenos Aires, Argentina; Breast Clinic, La Plata, Argentina
| | - J. O’Connor
- Hosp Udaondo, Buenos Aires, Argentina; Inst Alexander Fleming, Buenos Aires, Argentina; Breast Clinic, La Plata, Argentina
| | - G. Mendez
- Hosp Udaondo, Buenos Aires, Argentina; Inst Alexander Fleming, Buenos Aires, Argentina; Breast Clinic, La Plata, Argentina
| | - M. Chacón
- Hosp Udaondo, Buenos Aires, Argentina; Inst Alexander Fleming, Buenos Aires, Argentina; Breast Clinic, La Plata, Argentina
| | - M. Barugel
- Hosp Udaondo, Buenos Aires, Argentina; Inst Alexander Fleming, Buenos Aires, Argentina; Breast Clinic, La Plata, Argentina
| | - F. Marmissolle
- Hosp Udaondo, Buenos Aires, Argentina; Inst Alexander Fleming, Buenos Aires, Argentina; Breast Clinic, La Plata, Argentina
| | - M. Amat
- Hosp Udaondo, Buenos Aires, Argentina; Inst Alexander Fleming, Buenos Aires, Argentina; Breast Clinic, La Plata, Argentina
| | - E. Domenichini
- Hosp Udaondo, Buenos Aires, Argentina; Inst Alexander Fleming, Buenos Aires, Argentina; Breast Clinic, La Plata, Argentina
| | - E. Roca
- Hosp Udaondo, Buenos Aires, Argentina; Inst Alexander Fleming, Buenos Aires, Argentina; Breast Clinic, La Plata, Argentina
| |
Collapse
|
40
|
Bernard O, Chachuat B, Hélias A, Le Dantec B, Sialve B, Steyer JP, Lardon L, Neveu P, Lambert S, Gallop J, Dixon M, Ratini P, Quintabà A, Frattesi S, Lema JM, Roca E, Ruiz G, Rodriguez J, Franco A, Vanrolleghem P, Zaher U, De Pauw DJW, De Neve K, Lievens K, Dochaine D, Schoefs O, Fibrianto H, Farina R, Alcaraz Gonzalez V, Gonzalez Alvarez V, Lemaire P, Martinez JA, Esandi F, Duclaud O, Lavigne JF. An integrated system to remote monitor and control anaerobic wastewater treatment plants through the internet. Water Sci Technol 2005; 52:457-64. [PMID: 16180464] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/04/2023]
Abstract
The TELEMAC project brings new methodologies from the Information and Science Technologies field to the world of water treatment. TELEMAC offers an advanced remote management system which adapts to most of the anaerobic wastewater treatment plants that do not benefit from a local expert in wastewater treatment. The TELEMAC system takes advantage of new sensors to better monitor the process dynamics and to run automatic controllers that stabilise the treatment plant, meet the depollution requirements and provide a biogas quality suitable for cogeneration. If the automatic system detects a failure which cannot be solved automatically or locally by a technician, then an expert from the TELEMAC Control Centre is contacted via the internet and manages the problem.
Collapse
Affiliation(s)
- O Bernard
- COMORE, INRIA, BP93, 06902 Sophia-Antipolis Cedex, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Chacon M, Wasserman E, Guercovich A, Öconnor J, Giornelli G, Coronado C, Barugel M, Roca E, Carraro S, Chacon R. Oxaliplatin (OXA) with weekly bolus 5-fluorouracil (FU) and low-dose leucovorin (ld-LV) in advanced colorectal cancer (ACRC) patients (pts): Report of safety and efficacy. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.3769] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- M. Chacon
- Fleming Institute, Buenos Aires, Argentina; FUCA, Buenos Aires, Argentina; Udaondo Hospital, Buenos Aires, Argentina
| | - E. Wasserman
- Fleming Institute, Buenos Aires, Argentina; FUCA, Buenos Aires, Argentina; Udaondo Hospital, Buenos Aires, Argentina
| | - A. Guercovich
- Fleming Institute, Buenos Aires, Argentina; FUCA, Buenos Aires, Argentina; Udaondo Hospital, Buenos Aires, Argentina
| | - J. Öconnor
- Fleming Institute, Buenos Aires, Argentina; FUCA, Buenos Aires, Argentina; Udaondo Hospital, Buenos Aires, Argentina
| | - G. Giornelli
- Fleming Institute, Buenos Aires, Argentina; FUCA, Buenos Aires, Argentina; Udaondo Hospital, Buenos Aires, Argentina
| | - C. Coronado
- Fleming Institute, Buenos Aires, Argentina; FUCA, Buenos Aires, Argentina; Udaondo Hospital, Buenos Aires, Argentina
| | - M. Barugel
- Fleming Institute, Buenos Aires, Argentina; FUCA, Buenos Aires, Argentina; Udaondo Hospital, Buenos Aires, Argentina
| | - E. Roca
- Fleming Institute, Buenos Aires, Argentina; FUCA, Buenos Aires, Argentina; Udaondo Hospital, Buenos Aires, Argentina
| | - S. Carraro
- Fleming Institute, Buenos Aires, Argentina; FUCA, Buenos Aires, Argentina; Udaondo Hospital, Buenos Aires, Argentina
| | - R. Chacon
- Fleming Institute, Buenos Aires, Argentina; FUCA, Buenos Aires, Argentina; Udaondo Hospital, Buenos Aires, Argentina
| |
Collapse
|
42
|
Chacon M, Roca E, Barugel M, Jankilevich G, Giacomi N, Pelati M, Kowalyszyn R, Domenechini E, Galich M, Huertas E. Report of solid cancer in patients (pts) with gastrointestinal stromal tumours (GIST). J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.9065] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- M. Chacon
- Grupo argentino de tumores estromales (GATE-D), Buenos aires, Argentina
| | - E. Roca
- Grupo argentino de tumores estromales (GATE-D), Buenos aires, Argentina
| | - M. Barugel
- Grupo argentino de tumores estromales (GATE-D), Buenos aires, Argentina
| | - G. Jankilevich
- Grupo argentino de tumores estromales (GATE-D), Buenos aires, Argentina
| | - N. Giacomi
- Grupo argentino de tumores estromales (GATE-D), Buenos aires, Argentina
| | - M. Pelati
- Grupo argentino de tumores estromales (GATE-D), Buenos aires, Argentina
| | - R. Kowalyszyn
- Grupo argentino de tumores estromales (GATE-D), Buenos aires, Argentina
| | - E. Domenechini
- Grupo argentino de tumores estromales (GATE-D), Buenos aires, Argentina
| | - M. Galich
- Grupo argentino de tumores estromales (GATE-D), Buenos aires, Argentina
| | - E. Huertas
- Grupo argentino de tumores estromales (GATE-D), Buenos aires, Argentina
| |
Collapse
|
43
|
Vallejos C, Varela M, Roca E, Martinez J, Van Cutsem E, Misset JL, Louvet C, Cvitkovic E, MacDonald J, Wasserman E. Phase II trial of irofulven (IROF) and CPT-11 in metastatic colorectal cancer (MCRC) patients (pts) failing oxaliplatin (OXA)/5FU based chemotherapy. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.3713] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- C. Vallejos
- INEN, Lima, Peru; Hospital Italiano, Buenos Aires, Argentina; Hospital B. Udaondo, Buenos Aires, Argentina; Hospital Britanico, Buenos Aires, Argentina; University Hospital Gasthuisberg, Leuven, Belgium; Hôpital St Louis, Paris, France; Hôpital St Antoine, Paris, France; CAC, Le Kremlin-Bicêtre, France; MGI PHARMA Inc., Bloomington, MN; CAC, Buenos Aires, Argentina
| | - M. Varela
- INEN, Lima, Peru; Hospital Italiano, Buenos Aires, Argentina; Hospital B. Udaondo, Buenos Aires, Argentina; Hospital Britanico, Buenos Aires, Argentina; University Hospital Gasthuisberg, Leuven, Belgium; Hôpital St Louis, Paris, France; Hôpital St Antoine, Paris, France; CAC, Le Kremlin-Bicêtre, France; MGI PHARMA Inc., Bloomington, MN; CAC, Buenos Aires, Argentina
| | - E. Roca
- INEN, Lima, Peru; Hospital Italiano, Buenos Aires, Argentina; Hospital B. Udaondo, Buenos Aires, Argentina; Hospital Britanico, Buenos Aires, Argentina; University Hospital Gasthuisberg, Leuven, Belgium; Hôpital St Louis, Paris, France; Hôpital St Antoine, Paris, France; CAC, Le Kremlin-Bicêtre, France; MGI PHARMA Inc., Bloomington, MN; CAC, Buenos Aires, Argentina
| | - J. Martinez
- INEN, Lima, Peru; Hospital Italiano, Buenos Aires, Argentina; Hospital B. Udaondo, Buenos Aires, Argentina; Hospital Britanico, Buenos Aires, Argentina; University Hospital Gasthuisberg, Leuven, Belgium; Hôpital St Louis, Paris, France; Hôpital St Antoine, Paris, France; CAC, Le Kremlin-Bicêtre, France; MGI PHARMA Inc., Bloomington, MN; CAC, Buenos Aires, Argentina
| | - E. Van Cutsem
- INEN, Lima, Peru; Hospital Italiano, Buenos Aires, Argentina; Hospital B. Udaondo, Buenos Aires, Argentina; Hospital Britanico, Buenos Aires, Argentina; University Hospital Gasthuisberg, Leuven, Belgium; Hôpital St Louis, Paris, France; Hôpital St Antoine, Paris, France; CAC, Le Kremlin-Bicêtre, France; MGI PHARMA Inc., Bloomington, MN; CAC, Buenos Aires, Argentina
| | - J. L. Misset
- INEN, Lima, Peru; Hospital Italiano, Buenos Aires, Argentina; Hospital B. Udaondo, Buenos Aires, Argentina; Hospital Britanico, Buenos Aires, Argentina; University Hospital Gasthuisberg, Leuven, Belgium; Hôpital St Louis, Paris, France; Hôpital St Antoine, Paris, France; CAC, Le Kremlin-Bicêtre, France; MGI PHARMA Inc., Bloomington, MN; CAC, Buenos Aires, Argentina
| | - C. Louvet
- INEN, Lima, Peru; Hospital Italiano, Buenos Aires, Argentina; Hospital B. Udaondo, Buenos Aires, Argentina; Hospital Britanico, Buenos Aires, Argentina; University Hospital Gasthuisberg, Leuven, Belgium; Hôpital St Louis, Paris, France; Hôpital St Antoine, Paris, France; CAC, Le Kremlin-Bicêtre, France; MGI PHARMA Inc., Bloomington, MN; CAC, Buenos Aires, Argentina
| | - E. Cvitkovic
- INEN, Lima, Peru; Hospital Italiano, Buenos Aires, Argentina; Hospital B. Udaondo, Buenos Aires, Argentina; Hospital Britanico, Buenos Aires, Argentina; University Hospital Gasthuisberg, Leuven, Belgium; Hôpital St Louis, Paris, France; Hôpital St Antoine, Paris, France; CAC, Le Kremlin-Bicêtre, France; MGI PHARMA Inc., Bloomington, MN; CAC, Buenos Aires, Argentina
| | - J. MacDonald
- INEN, Lima, Peru; Hospital Italiano, Buenos Aires, Argentina; Hospital B. Udaondo, Buenos Aires, Argentina; Hospital Britanico, Buenos Aires, Argentina; University Hospital Gasthuisberg, Leuven, Belgium; Hôpital St Louis, Paris, France; Hôpital St Antoine, Paris, France; CAC, Le Kremlin-Bicêtre, France; MGI PHARMA Inc., Bloomington, MN; CAC, Buenos Aires, Argentina
| | - E. Wasserman
- INEN, Lima, Peru; Hospital Italiano, Buenos Aires, Argentina; Hospital B. Udaondo, Buenos Aires, Argentina; Hospital Britanico, Buenos Aires, Argentina; University Hospital Gasthuisberg, Leuven, Belgium; Hôpital St Louis, Paris, France; Hôpital St Antoine, Paris, France; CAC, Le Kremlin-Bicêtre, France; MGI PHARMA Inc., Bloomington, MN; CAC, Buenos Aires, Argentina
| |
Collapse
|
44
|
Lú-Chau TA, Guillán A, Núñez MJ, Roca E, Lema JM. Anaerobic and aerobic continuous cultures of Saccharomyces cerevisiae : comparison of plasmid stability and EXG1 gene expression. Bioprocess Biosyst Eng 2004; 26:159-63. [PMID: 14986091 DOI: 10.1007/s00449-003-0344-y] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2003] [Accepted: 12/09/2003] [Indexed: 11/28/2022]
Abstract
Two bioreactor continuous cultures, at anaerobic and aerobic conditions, were carried out using a recombinant Saccharomyces cerevisiae strain that over-expresses the homologous gene EXG1. This recombinant system was used to study the effect of dissolved oxygen concentration on plasmid stability and gene over-expression. Bioreactor cultures were operated at two dilution rates (0.14 and 0.03 h(-1)) to investigate the effect of other process parameters on EXG1 expression. Both cultures suffered severe plasmid instability during the first 16 generations. Segregational plasmid loss rate for the aerobic culture was two-fold that of the anaerobic operation. In spite of this fact, exo-beta-glucanase activity at aerobic conditions was 12-fold that of the anaerobic culture. This maximal activity (30 U ml(-1)) was attained at the lowest dilution rate when biomass reached its greatest value and glucose concentration was zero.
Collapse
Affiliation(s)
- T A Lú-Chau
- Department of Chemical Engineering, Institute of Technology, University of Santiago de Compostela, E-15706 Santiago de Compostela, Spain.
| | | | | | | | | |
Collapse
|
45
|
Franco A, Roca E, Lema JM. Improvement of the properties of granular sludge in UASB reactors by flow pulsation. Water Sci Technol 2003; 48:51-56. [PMID: 14640199] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/24/2023]
Abstract
The objective of this work is to improve the characteristics of granular sludge by modification of the hydraulics of the bed through flow pulsation. Three UASB reactors, two operated with pulsing flow (P1 and P2) and a third without pulsation (NP), were started-up. Both recycling and feeding flow were pulsed in the reactor P1, while in reactor P2, only the feeding was pulsed. A high increase in the removal capacity and stability were achieved by applying pulsation in reactors P1 and P2 when compared to the non-pulsed one. Besides, pulsation promotes the formation of particles of smaller size and higher porosity, thus increasing the specific surface of the bed and consequently, the specific activity. In fact, while reactors P1 and P2 had a 95% COD removal when working at high organic loading rates (12 kg COD/m3 x d), reactor NP only reached 6 kg COD/m3 x d with 85% of removal capacity.
Collapse
Affiliation(s)
- A Franco
- Dept. of Chemical Engineering, Institute of Technology, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | | | | |
Collapse
|
46
|
Yonni F, Fasoli HJ, Roca E, Feijoo G. Effect of heavy metals on the degradative activity by wood-rotting fungi. Bull Environ Contam Toxicol 2002; 68:752-759. [PMID: 12068944 DOI: 10.1007/s001280318] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/23/2023]
Affiliation(s)
- F Yonni
- Laboratory of Chemistry, School of Applied Sciences, Grl. Div. Manuel N. Savio, Buenos Aires, Argentina
| | | | | | | |
Collapse
|
47
|
Abstract
In this paper, an expert system (ES) developed for the monitoring and diagnosis of anaerobic wastewater treatment plants (AWT), is presented. The system was evaluated in a hybrid pilot plant of 1.1 m3 located in an industrial environment for the treatment of wastewaters from a fibreboard production factory. The reactor is a hybrid USBF, combining an upflow anaerobic sludge blanket (UASB) in the lower part and an upflow anaerobic filter (UAF) at the top.
Collapse
Affiliation(s)
- A Puñal
- Department of Chemical Engineering, Institute of Technology, University of Santiago de Compostela, Spain
| | | | | |
Collapse
|
48
|
Franco A, Gresia G, Roca E, Rozzi A, Lema JM. Influence of pulsation on start-up of UASB reactors. Water Sci Technol 2002; 45:163-168. [PMID: 12188538] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/23/2023]
Abstract
The aim of this work is to study the influence of pulsation on the start-up of lab-scale UASB reactors. Pulsation was produced by an Elastic Membrane Pulsator (EMP). The application of this device in previous works improved the performance of continuous fixed-bed fermentors and reduced the formation of preferential pathways, the retention of gas metabolites within the bed and the resistance to mass transfer. These characteristics seem to be suitable for feeding UASB reactors. In this work, the influence of pulsation frequency was studied in two pulsed UASB reactors operated in parallel with a non-pulsed one. One of them (P1) operated at high frequencies (periods of 50 and 200 s between each pulsation) and the other (P2) at low frequencies (periods of 3600 and 900 s between each pulsation). An important improvement of the removal efficiency for pulsed reactors with respect to the non-pulsed one was obtained. The structure of the biomass was observed at the end of the process by scanning electron microscopy. In general, granulation of biomass was improved when operating in pulsing form.
Collapse
Affiliation(s)
- A Franco
- Department of Chemical Engineering, Institute of Technology, University of Santiago de Compostela, Spain
| | | | | | | | | |
Collapse
|
49
|
Puñal A, Rodríguez J, Carrasco EF, Roca E, Lema JM. Expert system for the on-line diagnosis of anaerobic wastewater treatment plants. Water Sci Technol 2002; 45:195-200. [PMID: 12188544] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/23/2023]
Abstract
A diagnosis system for anaerobic wastewater treatment processes is presented. The system is able to recognise the state and trend of the operation and suggest the appropriate control action. The on-line variables measured were gas flow rate and composition (methane and carbon monoxide), feed and recycling flow rates, temperature and pH, while the manipulable inputs are feed, recycling and buffer-addition flow rates. The diagnosis system comprises a structured rule base, incorporating expert knowledge using fuzzy logic features. The structure of the system is based on the classification of information related to the process in three categories: i) the state of the process, ii) its trend and iii) the recommended set-point values for the inputs manipulated: feeding, buffer and recycling pumps. The system was applied to diagnose the operation of a 1.1 m3 hybrid UASB-UAF treating wastewater from a fibreboard production factory under different conditions (overload and underload), corresponding to some of the typical causes of destabilisation in anaerobic wastewater treatment plants. These situations require control action in order to maintain the stability and the treatment capacity of the reactor. The application of the system developed for the purpose of managing the situation proved to be reliable for supplying the actual state and trend of the process, as well as the adequate set point values to recover stable operation and/or to avoid further destabilisation.
Collapse
Affiliation(s)
- A Puñal
- Department of Chemical Engineering, Institute of Technology, University of Santiago de Compostela. Spain
| | | | | | | | | |
Collapse
|
50
|
Lú Chau T, Guillán A, Roca E, Núñez MJ, Lema JM. Population dynamics of a continuous fermentation of recombinant Saccharomyces cerevisiae using flow cytometry. Biotechnol Prog 2001; 17:951-7. [PMID: 11587589 DOI: 10.1021/bp010090r] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
The plasmid instability of genetically modified microorganisms during prolonged bioreactor operations is one of the major problems to be overcome in the production of recombinant proteins. The use of flow cytometry to monitor a fermentation process with recombinant cells in a CSTR is reported here. This technique has been applied to determine the fraction of plasmid-bearing cells (P+) of a recombinant Saccharomyces cerevisiae strain harboring the EXG1 gene in a continuous stirred tank bioreactor with a working volume of 2 L. The different levels in the expression of the EXG1 gene, which encodes the enzyme exo-beta-glucanase, were used to determine the P+ fraction. Other parameters such as viability, cellular protein, cell size and structure were also monitored using flow cytometry. This technique has two main advantages over the conventional method of determining the P+ fraction (plating in selective and non-selective solid media): (a) it takes a very short period of time to obtain a measurement that provides multiple parametric information; and (b) it is more representative of the bioreactor cell population since it can analyze thousands of cells in the same sample. A continuous operation (432 h) with the recombinant strain in a CSTR was carried out to test the application of this technique. Measurements of cellular exo-beta-glucanase activity and cellular protein content closely correlates to the measured fraction of plasmid-containing cells in the population. Moreover, the standard deviation of the fraction of P+ cells determined using this technique was very low (about 2%). Recombinant protein production also increased the size of the yeast cells, whereas the recombinant cells also had a more complex internal structure than the non-recombinant host strain.
Collapse
Affiliation(s)
- T Lú Chau
- Department of Chemical Engineering. Institute of Technology, Alfonso X el sabio. 27002-Lugo, Spain
| | | | | | | | | |
Collapse
|